surmount-osa trial tirzepatide results SURMOUNT-1 SURMOUNT-3 study design This is

In the pivotal SURMOUNT-1 clinical trial, participants taking the highest dose of tirzepatide achieved an average body weight reduction of up to 22.5% over 72 weeks

Or rather, it tells an incomplete truth

doi: 10.1016/S0140-6736(21)01443-4 [DOI] [PubMed] [Google Scholar] 7

Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with an increased risk of suicidal thoughts and behavior

(aad.org) In our Sherman Oaks practice: pigment on the chest often lasts longer than patients expect because year-round sun exposure keeps re-darkening recently healed lesions

This is actually one of the main advantages of the 20mg/ml formulation